JP2023549605A - 非結核性マイコバクテリア疾患の治療におけるベダキリン、エタンブトール、及びマクロライドの組合せ - Google Patents

非結核性マイコバクテリア疾患の治療におけるベダキリン、エタンブトール、及びマクロライドの組合せ Download PDF

Info

Publication number
JP2023549605A
JP2023549605A JP2023528411A JP2023528411A JP2023549605A JP 2023549605 A JP2023549605 A JP 2023549605A JP 2023528411 A JP2023528411 A JP 2023528411A JP 2023528411 A JP2023528411 A JP 2023528411A JP 2023549605 A JP2023549605 A JP 2023549605A
Authority
JP
Japan
Prior art keywords
bedaquiline
week
combination
clarithromycin
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549605A5 (https=
Inventor
健 黒沢
マハデヴァン，シヴィ
カンビリ，クリスピン
忠石 ▲高▼
ルイス エフ ロッセヌ，ステファーン
マーサ エム ウィレムス，ウーター
エリセ ビウェンガ，ジェイク
ギルバート アラン アーノルト，エティエンヌ
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2023549605A publication Critical patent/JP2023549605A/ja
Publication of JP2023549605A5 publication Critical patent/JP2023549605A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023528411A 2020-11-12 2021-11-10 非結核性マイコバクテリア疾患の治療におけるベダキリン、エタンブトール、及びマクロライドの組合せ Pending JP2023549605A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063113149P 2020-11-12 2020-11-12
US63/113,149 2020-11-12
PCT/EP2021/081193 WO2022101244A1 (en) 2020-11-12 2021-11-10 Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases

Publications (2)

Publication Number Publication Date
JP2023549605A true JP2023549605A (ja) 2023-11-28
JP2023549605A5 JP2023549605A5 (https=) 2024-11-27

Family

ID=78695693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528411A Pending JP2023549605A (ja) 2020-11-12 2021-11-10 非結核性マイコバクテリア疾患の治療におけるベダキリン、エタンブトール、及びマクロライドの組合せ

Country Status (7)

Country Link
US (1) US20230346770A1 (https=)
EP (1) EP4243800A1 (https=)
JP (1) JP2023549605A (https=)
KR (1) KR20230107275A (https=)
CN (1) CN116406270A (https=)
TW (1) TW202233168A (https=)
WO (1) WO2022101244A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250169098A (ko) 2024-05-24 2025-12-02 주식회사 에이엔제이사이언스 티오펩타이드 화합물을 포함하는 비결핵 항산균 감염증의 예방, 개선 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020144197A1 (en) * 2019-01-09 2020-07-16 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1527050T3 (da) 2002-07-25 2010-07-19 Janssen Pharmaceutica Nv Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
AU2005249231B2 (en) 2004-05-28 2010-11-11 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
UA97813C2 (uk) 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
LT3250182T (lt) * 2015-01-27 2023-07-10 Janssen Pharmaceutica Nv Dispersinės kompozicijos
JOP20200004B1 (ar) * 2017-07-14 2023-09-17 Janssen Pharmaceutica Nv تركيبات طويلة المفعول

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020144197A1 (en) * 2019-01-09 2020-07-16 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEST, vol. Vol.148, No.2, pp.499-506, JPN6025041419, 2015, ISSN: 0005707624 *

Also Published As

Publication number Publication date
WO2022101244A1 (en) 2022-05-19
CN116406270A (zh) 2023-07-07
US20230346770A1 (en) 2023-11-02
EP4243800A1 (en) 2023-09-20
KR20230107275A (ko) 2023-07-14
TW202233168A (zh) 2022-09-01

Similar Documents

Publication Publication Date Title
Philley et al. Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease
Bailo et al. Lipid transport in Mycobacterium tuberculosis and its implications in virulence and drug development
Kobashi et al. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease
Hurst et al. Levofloxacin: an updated review of its use in the treatment of bacterial infections
KR20210113628A (ko) 비결핵성 마이코박테리아 질환의 치료에서의 조합물
Hoover et al. Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers
US11926862B2 (en) Pharmaceutical compositions for prevention and/or treatment of infections and antibacterial-induced dysfunctions
Hoover et al. Single and multiple ascending-dose studies of oral delafloxacin: effects of food, sex, and age
CN106620649A (zh) 使用单剂量奥利万星的治疗方法
JP2023549605A (ja) 非結核性マイコバクテリア疾患の治療におけるベダキリン、エタンブトール、及びマクロライドの組合せ
Jacobson et al. Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network
JP2022539583A (ja) マイコプラズマ・ジェニタリウムによって引き起こされる感染症の治療のための組合せ
Nicholson et al. Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly
Shrestha et al. In vitro antifungal effect of mouth rinses containing chlorhexidine and thymol
HK40096376A (zh) 在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合
Chua Metronidazole
HK40050798A (en) Combination in the treatment of nontuberculous mycobacterial diseases
CN119564683B (zh) 一种抗分枝杆菌感染的联合增效药物组合物
Rashid et al. Effect of telavancin on human intestinal microflora
Sahu et al. mucormycosis in indian covid-19 patients: insight into its patho-genesis, clinical manifestation, and management strategies. Antibiotics 2021; 10
Wang Reviving disused antibiotics against Gram-negative ESKAPE pathogens: combination with the polyaminoisoprenyl potentiator NV716
Di Stefano et al. Efficacy of the treatment of infectious diarrhoea with non-absorbable rifamycin SV formulated as MMX modified release tablet vs. rifaximin
KR20240148317A (ko) 비-결핵 미코박테리아 감염 치료
Alan et al. Rifampicin (Rifampin)
Cole et al. Highlights from the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260414